{"log_id": 7213735434683259808, "direction": 0, "words_result_num": 62, "words_result": [{"probability": {"variance": 0, "average": 0.980524, "min": 0.980524}, "location": {"width": 27, "top": 164, "height": 23, "left": 1144}, "words": "药"}, {"probability": {"variance": 0, "average": 0.717648, "min": 0.717648}, "location": {"width": 37, "top": 198, "height": 26, "left": 1144}, "words": "准"}, {"probability": {"variance": 0.000103, "average": 0.995756, "min": 0.936694}, "location": {"width": 787, "top": 249, "height": 35, "left": 226}, "words": "时达到ACR20的患者百分比。第52周的联合主要终点为托珠单抗联合MTX对类风湿关节炎"}, {"probability": {"variance": 2e-06, "average": 0.998969, "min": 0.993904}, "location": {"width": 340, "top": 294, "height": 27, "left": 226}, "words": "关节破坏进展的抑制和身体功能的改善"}, {"probability": {"variance": 0.007602, "average": 0.979652, "min": 0.428857}, "location": {"width": 745, "top": 329, "height": 32, "left": 268}, "words": "研究评价了623名对MTX治疗临床反应不佳的患者。每四周给予一次4或8mg/kg的"}, {"probability": {"variance": 0.00329, "average": 0.984519, "min": 0.632781}, "location": {"width": 786, "top": 368, "height": 34, "left": 228}, "words": "托珠单抗或安慰剂,同时联用稳定剂量的MTX(10~25mg/周)。研究Ⅳ评价了1220名对"}, {"probability": {"variance": 5.9e-05, "average": 0.997501, "min": 0.952902}, "location": {"width": 785, "top": 407, "height": 33, "left": 229}, "words": "现有风湿病治疗方案临床反应不佳的患者,这些治疗包括一种或多种 DMARDS.。每四周给"}, {"probability": {"variance": 0.000604, "average": 0.989535, "min": 0.893588}, "location": {"width": 783, "top": 445, "height": 34, "left": 230}, "words": "予一次8mg/kg的托珠单抗或安慰剂,同时联用稳定剂量的 DMARD。研究V评价了499名"}, {"probability": {"variance": 1e-05, "average": 0.997942, "min": 0.985399}, "location": {"width": 786, "top": 484, "height": 34, "left": 229}, "words": "对一种或多种抗肿瘤坏死因子(TNF)治疗反应不佳或不能耐受的患者。在随机前已停止"}, {"probability": {"variance": 5.6e-05, "average": 0.996803, "min": 0.952719}, "location": {"width": 786, "top": 524, "height": 32, "left": 230}, "words": "使用抗TNF制剂治疗。每四周给予一次4或8mg/kg的托珠单抗或安慰剂,同时联用稳定剂"}, {"probability": {"variance": 0.007196, "average": 0.967479, "min": 0.590913}, "location": {"width": 783, "top": 563, "height": 33, "left": 229}, "words": "量的MTX(10~25mg/周)。研究Ⅲ~V的主要终点是在治疗的第24周时达到ACR20的患者"}, {"probability": {"variance": 0, "average": 0.999245, "min": 0.998744}, "location": {"width": 62, "top": 610, "height": 24, "left": 231}, "words": "百分比"}, {"probability": {"variance": 0.000265, "average": 0.987813, "min": 0.936776}, "location": {"width": 580, "top": 644, "height": 30, "left": 271}, "words": "研究I~V中患者达到ACR20、ACR50和ACR70的百分比见表2"}, {"probability": {"variance": 0.009355, "average": 0.969426, "min": 0.562505}, "location": {"width": 515, "top": 682, "height": 32, "left": 272}, "words": "表2MTX安慰剂对照研究中ACR应答情况(患者百分比)"}, {"probability": {"variance": 0.003137, "average": 0.95925, "min": 0.880048}, "location": {"width": 48, "top": 724, "height": 20, "left": 811}, "words": "研究Ⅳ"}, {"probability": {"variance": 0.010261, "average": 0.92585, "min": 0.782594}, "location": {"width": 54, "top": 722, "height": 20, "left": 980}, "words": "研究V"}, {"probability": {"variance": 0.000319, "average": 0.987191, "min": 0.96193}, "location": {"width": 53, "top": 739, "height": 22, "left": 294}, "words": "研究I"}, {"probability": {"variance": 0.005887, "average": 0.945207, "min": 0.836698}, "location": {"width": 52, "top": 738, "height": 20, "left": 466}, "words": "研究I"}, {"probability": {"variance": 0.021288, "average": 0.895009, "min": 0.688674}, "location": {"width": 52, "top": 737, "height": 20, "left": 638}, "words": "研究Ⅲ"}, {"probability": {"variance": 1e-06, "average": 0.998643, "min": 0.997506}, "location": {"width": 105, "top": 747, "height": 20, "left": 783}, "words": "对 DMARD反应"}, {"probability": {"variance": 0.000109, "average": 0.993823, "min": 0.968772}, "location": {"width": 101, "top": 745, "height": 21, "left": 956}, "words": "对TNF抑制剂"}, {"probability": {"variance": 0.001816, "average": 0.977031, "min": 0.816714}, "location": {"width": 473, "top": 760, "height": 24, "left": 252}, "words": "未接受过MTX治疗对MTX反应不佳对MTX反应不佳"}, {"probability": {"variance": 3e-06, "average": 0.997746, "min": 0.995889}, "location": {"width": 34, "top": 770, "height": 22, "left": 822}, "words": "不佳"}, {"probability": {"variance": 0.000182, "average": 0.991558, "min": 0.9682}, "location": {"width": 65, "top": 770, "height": 19, "left": 977}, "words": "反应不住"}, {"probability": {"variance": 0, "average": 0.816931, "min": 0.816931}, "location": {"width": 22, "top": 799, "height": 17, "left": 270}, "words": " ICZ"}, {"probability": {"variance": 0.00468, "average": 0.968156, "min": 0.686519}, "location": {"width": 639, "top": 790, "height": 27, "left": 438}, "words": "TZ安慰剂TCZ安慰剂TCZ安慰剂TCZ安慰剂"}, {"probability": {"variance": 0.000575, "average": 0.983904, "min": 0.929264}, "location": {"width": 136, "top": 820, "height": 38, "left": 170}, "words": "反应率8mg/k"}, {"probability": {"variance": 0.006674, "average": 0.858924, "min": 0.801608}, "location": {"width": 41, "top": 823, "height": 16, "left": 433}, "words": " ng/kg"}, {"probability": {"variance": 0.000715, "average": 0.968731, "min": 0.919163}, "location": {"width": 118, "top": 820, "height": 19, "left": 523}, "words": " MTX 8mg/kg"}, {"probability": {"variance": 0, "average": 0.477054, "min": 0.477054}, "location": {"width": 21, "top": 820, "height": 18, "left": 697}, "words": " MT"}, {"probability": {"variance": 0.02399, "average": 0.882231, "min": 0.571758}, "location": {"width": 192, "top": 818, "height": 18, "left": 793}, "words": "kg++DMARD 8mg/kg"}, {"probability": {"variance": 0, "average": 1, "min": 1}, "location": {"width": 32, "top": 817, "height": 17, "left": 1036}, "words": " +MTX"}, {"probability": {"variance": 0, "average": 0.973029, "min": 0.973029}, "location": {"width": 29, "top": 843, "height": 18, "left": 436}, "words": " MTX"}, {"probability": {"variance": 0, "average": 0.605417, "min": 0.605417}, "location": {"width": 19, "top": 843, "height": 17, "left": 608}, "words": " MT"}, {"probability": {"variance": 0, "average": 0.940807, "min": 0.940807}, "location": {"width": 40, "top": 843, "height": 16, "left": 771}, "words": " DMARI"}, {"probability": {"variance": 0, "average": 0.977932, "min": 0.977932}, "location": {"width": 18, "top": 841, "height": 16, "left": 953}, "words": " MT"}, {"probability": {"variance": 1e-06, "average": 0.999101, "min": 0.998299}, "location": {"width": 20, "top": 868, "height": 18, "left": 276}, "words": "28"}, {"probability": {"variance": 3e-06, "average": 0.997453, "min": 0.994704}, "location": {"width": 47, "top": 867, "height": 18, "left": 426}, "words": "N=398"}, {"probability": {"variance": 1.2e-05, "average": 0.993539, "min": 0.990038}, "location": {"width": 21, "top": 866, "height": 19, "left": 620}, "words": "05"}, {"probability": {"variance": 0.031703, "average": 0.894828, "min": 0.513308}, "location": {"width": 107, "top": 863, "height": 21, "left": 704}, "words": "204N=803"}, {"probability": {"variance": 9e-06, "average": 0.997071, "min": 0.994142}, "location": {"width": 19, "top": 862, "height": 18, "left": 944}, "words": " N="}, {"probability": {"variance": 6e-06, "average": 0.995442, "min": 0.993265}, "location": {"width": 40, "top": 860, "height": 19, "left": 1027}, "words": "N=15"}, {"probability": {"variance": 0.001715, "average": 0.972373, "min": 0.90098}, "location": {"width": 64, "top": 943, "height": 22, "left": 165}, "words": "第24周"}, {"probability": {"variance": 1.7e-05, "average": 0.995938, "min": 0.989289}, "location": {"width": 65, "top": 1000, "height": 20, "left": 166}, "words": "第52周"}, {"probability": {"variance": 0, "average": 0.950071, "min": 0.950071}, "location": {"width": 36, "top": 1048, "height": 18, "left": 172}, "words": " ACR5"}, {"probability": {"variance": 6e-06, "average": 0.997267, "min": 0.993764}, "location": {"width": 65, "top": 1098, "height": 23, "left": 168}, "words": "第24周"}, {"probability": {"variance": 1e-06, "average": 0.998942, "min": 0.997877}, "location": {"width": 62, "top": 1169, "height": 23, "left": 171}, "words": "第52周"}, {"probability": {"variance": 1.8e-05, "average": 0.996387, "min": 0.987497}, "location": {"width": 111, "top": 1266, "height": 23, "left": 171}, "words": "第24周28%"}, {"probability": {"variance": 2e-06, "average": 0.996864, "min": 0.995501}, "location": {"width": 20, "top": 1266, "height": 20, "left": 343}, "words": "5%"}, {"probability": {"variance": 0, "average": 0.999369, "min": 0.998775}, "location": {"width": 21, "top": 1262, "height": 21, "left": 676}, "words": "2%"}, {"probability": {"variance": 0, "average": 0.999191, "min": 0.998766}, "location": {"width": 17, "top": 1262, "height": 18, "left": 852}, "words": "3%"}, {"probability": {"variance": 7.5e-05, "average": 0.990851, "min": 0.981651}, "location": {"width": 62, "top": 1317, "height": 21, "left": 172}, "words": "第52周"}, {"probability": {"variance": 3.3e-05, "average": 0.992138, "min": 0.98642}, "location": {"width": 19, "top": 1316, "height": 20, "left": 427}, "words": "20"}, {"probability": {"variance": 7e-06, "average": 0.997164, "min": 0.99448}, "location": {"width": 20, "top": 1314, "height": 22, "left": 509}, "words": "4%"}, {"probability": {"variance": 0.000109, "average": 0.993038, "min": 0.974967}, "location": {"width": 64, "top": 1357, "height": 20, "left": 172}, "words": "第52周"}, {"probability": {"variance": 0, "average": 0.708977, "min": 0.708977}, "location": {"width": 22, "top": 1383, "height": 15, "left": 185}, "words": " CRT"}, {"probability": {"variance": 0.001399, "average": 0.981546, "min": 0.89029}, "location": {"width": 111, "top": 1404, "height": 26, "left": 290}, "words": "CZ=托珠单抗"}, {"probability": {"variance": 0.001902, "average": 0.977174, "min": 0.837527}, "location": {"width": 351, "top": 1443, "height": 24, "left": 277}, "words": "*p<0.05,托珠单抗对比安慰剂+ MTX/DMARD"}, {"probability": {"variance": 0.000468, "average": 0.988659, "min": 0.917973}, "location": {"width": 363, "top": 1475, "height": 27, "left": 281}, "words": "p<0.01,托珠单抗对比安慰剂 MTX/DMARD"}, {"probability": {"variance": 0.001653, "average": 0.983546, "min": 0.826178}, "location": {"width": 275, "top": 1510, "height": 22, "left": 393}, "words": "托珠单抗对比安慰剂+ MTX/DMARD"}, {"probability": {"variance": 0.000669, "average": 0.989404, "min": 0.859517}, "location": {"width": 517, "top": 1542, "height": 24, "left": 293}, "words": "MCR=主要临床应答,指ACR70反应可持续连续24周或以上的时间"}, {"probability": {"variance": 0, "average": 0.733044, "min": 0.733044}, "location": {"width": 133, "top": 1493, "height": 72, "left": 946}, "words": "斗"}], "language": 3}